NeurologyLive® Friday 5 — September 26, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Testing a Promising Remyelinating Agent for Relapsing-Remitting Multiple Sclerosis: The VISTA Trial

A new trial evaluates PIPE-307, a drug targeting M1 receptors, aiming to promote remyelination in relapsing-remitting multiple sclerosis patients.

2: The Changing Landscape of Epilepsy Care: Orrin Devinsky, MD

The director of NYU Langone’s Comprehensive Epilepsy Center highlighted recent progress in epilepsy care, spanning new therapies, gene-based approaches, mortality awareness, and improved pregnancy management. [WATCH TIME: 3 minutes]

3: World Narcolepsy Day: Raising Awareness for Earlier Recognition and Management

Dionne Morgan, MD, a sleep medicine physician at Baptist Health Miami Cardiac & Vascular Institute, provided commentary on World Narcolepsy Day, highlighting challenges in diagnosis and treatment, evolution in therapeutics, and combating comorbidities.

4: NeuroVoices: Rebecca Edelmayer, PhD, on the Alzheimer’s Association’s New Blood-Based Biomarker Guidelines

In our latest NeuroVoices Q&A, the vice president of scientific engagement at the Alzheimer’s Association discussed the organization’s recently published first guidelines on blood-based biomarkers, highlighting accuracy, clinical use, and patient considerations.

5: Key Risk Factors and Individualized Treatment Approaches in Early Childhood Stuttering

At the 2025 STARS Research & Education Conference, Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted risk factors and care interventions for stuttering in children.